Live Chat ×
Skip to main content

Update on the Latest Strategies to Diagnose and Treat Neurotrophic Keratitis: An Evening With the DAO - Thursday, December 3, 2020

Description


CME Webinar

Thursday, December 3, 2020
5:00 PM PST | 6:00 PM MST| 7:00 PM CST| 8:00 PM EST


Please click the REGISTER button on the right to register for the program. You will receive a confirmation email with a link to access the program. A reminder email closer to the date of the program will be sent as well.

Please take the pretest prior to accessing the program.


Please contact info@mededicus.com with any questions. Thank you!

FACULTY

Stephen C. Pflugfelder, MD
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
Houston, Texas

Karolinne M. Rocha, MD, PhD
Director, Cornea and Refractive Surgery Division
Medical University of South Carolina
Storm Eye Institute
Mt Pleasant, South Carolina

CONTINUING MEDICAL EDUCATION INFORMATION

Activity Description and Purpose
Neurotrophic keratitis is characterized by disrupted tearing and progressive corneal damage that does not readily heal. Until very recently, a lack of effective treatment to reinnervate and heal eyes affected by NK served to further hamper efforts toward timely diagnosis. Now that an effective treatment is available, ophthalmologists need to identify patients who might benefit from treatment before the disease progresses to the point of corneal perforation and subsequent loss of visual acuity. The desired results of this educational activity are for ophthalmologists to have a better understanding of the pathophysiology of NK as well as current best practices for screening, diagnosis, and treatment.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives
After completing this activity, participants will be better able to:
  • Describe the pathophysiology of neurotrophic keratitis
  • Integrate evaluation of corneal sensitivity into assessment of ocular surface disease 
  • Review evidence of corneal healing and reinnervation in patients treated with recombinant human nerve growth factor
  • Identify treatment strategies for patients diagnosed with any stage of neurotrophic keratitis

Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit
To obtain AMA PRA Category 1 Credit™ for this activity, participate in the webinar, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Faculty
Stephen C. Pflugfelder, MD, is a consultant for Dompé US, Inc, Kala Pharmaceuticals, KOWA Pharmaceuticals America, Inc, Novartis Pharmaceuticals Corporation, and Senju Pharmaceutical Co, Ltd; and is a contracted researcher for Dompé US, Inc, and Novartis Pharmaceuticals Corporation.

Karolinne M. Rocha, MD, PhD, is a consultant for Dompé US, Inc.

Peer Reviewer

Peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support

This continuing education activity is supported through an unrestricted educational grant from Dompé US, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.

This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 238

December 3, 2020
Thu 8:00 PM EST

Duration 1H 0M

Already Registered?